Rekvina Laboratories Limited has issued formal notice for its extraordinary general meeting scheduled for April 10, 2026, following the board's earlier approval of significant corporate restructuring initiatives including a major acquisition and capital enhancement measures.

EGM Details and Timeline

The company has scheduled its extraordinary general meeting for Friday, April 10, 2026, at 11:30 a.m. at the registered office in Vadodara. The notice was dispatched to shareholders on March 18, 2026, with the cut-off date set as March 13, 2026.

Authorized Share Capital Increase

Shareholders will vote on increasing the company's authorized share capital from ₹3,50,00,000/- divided into 70,00,000 equity shares to ₹6,00,00,000/- divided into 1,20,00,000 equity shares of ₹5/- face value each. This enhancement will facilitate the proposed preferential issues and future business requirements.

Major Acquisition Through Share Swap

The meeting agenda includes approval for acquiring 100% stake in Radiant Parenterals Limited for ₹4,62,77,500/- through share exchange. The company will issue 46,27,750 equity shares at ₹10/- per share to Radiant's existing shareholders.

Additional Preferential Issue

The agenda also covers issuing 4,60,000 equity shares at ₹10/- per share for cash consideration of ₹46,00,000/- to non-promoter investors, specifically Amitkumar Arunkumar Rao and Amitkumar Arunkumar Rao HUF.

Related Party Transactions and Investment Limits

Shareholders will consider approving related party transactions up to ₹4,62,77,500/- with Radiant Parenterals Limited and its stakeholders. The meeting will also address increasing investment limits under Section 186 of the Companies Act to ₹10 crore for loans, guarantees, and securities.

Regulatory Compliance and Voting Process

The company has appointed Suhas Bhattbhatt as scrutinizer for the voting process. Remote e-voting will be available from April 6, 2026 (9:00 AM) to April 9, 2026 (5:00 PM). The proposals require compliance with SEBI ICDR Regulations and other applicable securities laws, with valuation reports obtained from registered valuer Devang S. Thakar supporting the share exchange ratios.

Rekvina Laboratories Limited has formally disclosed to BSE Limited the receipt of a public announcement for an open offer by three acquirers, as mandated under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure, dated March 17, 2026, confirms the company's compliance with regulatory requirements following the public announcement issued by Vivro Financial Services Private Limited.

Open Offer Structure and Financial Details

The open offer involves three acquirers seeking to purchase equity shares from public shareholders of Rekvina Laboratories Limited. Vivro Financial Services Private Limited has been appointed as Manager to the Open Offer, with the transaction structured as a mandatory offer under SEBI (SAST) Regulations.

The offer price of ₹10 per share has been determined in accordance with Regulation 8(1) and 8(2) of the SEBI (SAST) Regulations. The transaction represents a triggered offer, making it mandatory under Regulations 3(2) and 4 of the SEBI (SAST) Regulations.

Acquirer Details and Shareholding Structure

The acquisition involves three individuals with varying current stakes in Rekvina Laboratories. The acquirers' pre-transaction and proposed post-transaction shareholdings demonstrate significant changes in the company's control structure.

Surbhit Mukesh Shah serves as Promoter and Managing Director of Rekvina Laboratories, while Amit Mukesh Shah holds the position of Promoter and Director. Dhruvalkumar Patel currently has no existing interest in the target company.

Underlying Transaction Details

The open offer was triggered by a Share Exchange and Purchase Agreement dated March 16, 2026. This agreement involves the acquisition of Radiant Parenterals Limited through a comprehensive share swap arrangement.

The board of directors of Rekvina Laboratories resolved on March 16, 2025, to issue 46,27,750 subscription shares of face value ₹5 each at ₹10 per share through preferential issue on a private placement basis.

Regulatory Compliance and Company Information

Rekvina Laboratories Limited, through Company Secretary & Compliance Officer Deepak Khandelwal, has ensured proper disclosure to BSE Limited and dissemination to shareholders. The company maintains its listing status on BSE Limited with established market presence.

Vivro Financial Services, registered with SEBI under registration number MB/INM000010122, will manage the open offer process in compliance with applicable regulations. The acquirers have undertaken to maintain adequate financial resources and have made firm financial arrangements for financing the acquisition. The detailed public statement will be published within 5 working days from the public announcement, containing comprehensive information about the offer including reasons, background, statutory approvals required, and financial arrangements.